MEASURE CHL-AD: CHLAMYDIA SCREENING IN WOMEN AGES 21 TO 24

National Committee for Quality Assurance

A. DESCRIPTION

Percentage of women ages 21 to 24 who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

Data Collection Method: Administrative or EHR

Guidance for Reporting:

- For HEDIS, this measure has three reportable rates—ages 16 to 20, ages 21 to 24, and a total (ages 16 to 24). The Adult Core Set measure applies to beneficiaries ages 21 to 24 and the Child Core Set measure applies to beneficiaries ages 16 to 20.
- Include all paid, suspended, pending, and denied claims.
- Beneficiaries in hospice are excluded from the eligible population. For additional information, refer to the hospice exclusion guidance in Section II. Data Collection and Reporting of the Adult Core Set.
- NCQA's Medication List Directory (MLD) for Contraceptive Medications and Retinoid Medications is available to order free of charge in the NCQA Store (http://store.ncqa.org/index.php/catalog/product/view/id/3741/s/hedis-2020-ndc). Once ordered, the Medication List Directory can be accessed through the NCQA Download Center (https://my.ncqa.org/?ReturnUrl=%2fDownloads).
- The electronic specification for FFY 2020 is located on the eCQI resource center at https://ecqi.healthit.gov/ecqm/ep/2019/cms153v7.

The following coding systems are used in this measure: CPT, HCPCS, ICD-10-CM, LOINC, NDC, RxNorm, SNOMED, and UB. Refer to the Acknowledgments section at the beginning of the manual for copyright information.

B. ELIGIBLE POPULATION

Age	Women ages 21 to 24 as of December 31 of the measurement year.
Continuous enrollment	The measurement year.
Allowable gap	No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a beneficiary for whom enrollment is verified monthly, the beneficiary may not have more than a 1-month gap in coverage (i.e., a beneficiary whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
Anchor date	December 31 of the measurement year.
Benefit	Medical.

Event/ diagnosis	Sexually active. Two methods identify sexually active women: pharmacy data and claims/encounter data. The state must use both methods to identify the eligible population; however, a beneficiary only needs to be identified in one method to be eligible for this measure. Claim/encounter data. Beneficiaries who had a claim or encounter indicating sexual activity during the measurement year. A code from any of the following meets criteria: • Pregnancy Value Set • Sexual Activity Value Set • Pregnancy Tests Value Set Pharmacy data. Beneficiaries who were dispensed prescription contraceptives during the measurement year (Contraceptive Medications List, see link to the Medication List Directory in Guidance for Reporting above).

C. ADMINISTRATIVE SPECIFICATION

Denominator

The eligible population as defined above.

Numerator

At least one chlamydia test (Chlamydia Tests Value Set) during the measurement year.

Exclusions (optional)

Exclude women who qualified for the denominator based on a pregnancy test (Pregnancy Tests Value Set) alone and who meet either of the following:

- A pregnancy test (Pregnancy Test Exclusion Value Set) during the measurement year and a prescription for isotretinoin (Retinoid Medications List, see link to the Medication List Directory in Guidance for Reporting above) on the date of the pregnancy test or within the 6 days after the pregnancy test
- A pregnancy test (Pregnancy Test Exclusion Value Set) during the measurement year and an x-ray (Diagnostic Radiology Value Set) on the date of the pregnancy test or within the 6 days after the pregnancy test